← All trials
NCT07067801
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2028
- First posted
- Jul 16, 2025
- Last posted
- Jul 24, 2025
- Enrollment
- 430
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Franche-ComtéLead sponsor
- University of BurgundyCollaborator
- University of ReimsCollaborator
- University of StrasbourgCollaborator
- CHU BesançonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.